Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Jonathan W. Riess(University of California Davis Medical Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Mark Dunphy(Memorial Sloan Kettering Cancer Center), Joel M. Reid(Children's Hospital of Philadelphia), David R. Gandara(University of California, Davis), Charles A. Kunos(National Cancer Institute), Simon R. Cherry(University of California, Davis), Ramsey D. Badawi(University of California, Davis), Wilson I. Gonsalves(Mayo Clinic in Arizona), Primo N. Lara(UC Davis Comprehensive Cancer Center), David B. Shackelford(University of California, Los Angeles), Edward M. Newman(City of Hope), Paul Frankel(City of Hope), Ian R. Lanza(Mayo Clinic), Lorenzo Nardo(University of California, San Francisco)
Cited by 65
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k